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In vitro elucidation of the crucial but complex
oxidative tailoring steps in rufomycin biosynthesis
enables one pot conversion of rufomycin B to
rufomycin C†
Gustavo Perez Ortiz,a John D. Sidda,‡a Emmanuel L. C. de los Santos, §b
Catherine B. Hubert ¶a and Sarah M. Barry *a
The antimycobacterial peptides, rufomycins, have their antibiotic
activity conferred by oxidative tailoring of the cyclic peptide. Here
we elucidate the roles of cytochrome P450s RufS and RufM in
regioselective epoxidation and alkyl oxidation respectively and
demonstrate how RufM and RufS create a complex product profile
dependent on redox partner availability. Finally, we report the
in vitro one pot conversion of rufomycin B to rufomycin C.
Cytochromes P450 (CYPs) are a large family of heme dependent
redox enzymes that activate molecular oxygen to catalyze an
array of transformations including oxidative C–C bond for-
mation, hydroxylation and epoxidation.1 CYPs have diverse
roles in many organisms including biosynthetic and degrada-
tive pathways. CYP catalysed oxidation is a frequent feature of
non-ribosomal peptide, polyketide and terpene biosynthesis,
including modifications to biosynthetic precursors, growing
polyketide or non-ribosomal peptide chains or post-
cyclisation scaffolds. Such modifications are crucial in the
biosynthesis of several clinically used antibiotics including
vancomycin, rifampicin and erythromycin.2 While the most
common reaction catalysed by CYPs is hydroxylation, biosyn-
thetic CYPs, despite a highly conserved tertiary structure,
demonstrate exceptional chemical versatility including sequen-
tial oxidation, nitration, C–C bond formation, N-glycosylation
and decarboxylation.2 The discovery of new oxidative chemistry,
combined with their ability to activate inert C–H bonds on both
small and highly complex molecules with exceptional regio and
stereoselectivity, has also led to renewed interest in CYPs as
potential biocatalysts.3–5
In the biosynthesis of the non-ribosomal peptides, rufomy-
cins (also known as ilamycins), CYPs introduce epoxide and
carbonyl moieties vital for biological activity (Fig. 1 and ESI,†
Fig. S5).6 Rufomycins have anticancer activity but have
attracted recent interest due to their selective activity against
Mycobacterium tuberculosis (Mtb), the causative agent of TB and
a leading cause of death from a single infectious agent.7–9
Multidrug resistance to frontline antibiotics, rifampicin and
isoniazid, is rising, leading to a need for new TB antibiotics.9,10
Fig. 1 Biosynthetic steps to rufomycins and cyclomarins. Top: Oxidative
tailoring of rufomycin B by RufS and RufM or homologues IlaR and IlaL.
Steps previously proven (black solid arrows),15 this work (red solid), not
demonstrated by experiment (black dashed). Inset: Proposed role of CymS
in cyclomarin biosynthesis, structures of shunt metabolites rufomyazine,
cyclomarazine and antibiotic cyclomarin A.
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Rufomycins, like the structurally similar cyclomarins, are cova-
lent inhibitors of the Mtb protease ClpC1. Binding is facilitated
via ring opening of the epoxide moiety.11,12 Rufomycins are
produced as a mixture of variously oxidised derivatives by
several Streptomyces strains8,13,14 (ESI,† Fig. S5). NRPS, RufT,
assembles the core cyclic peptide rufomycin B 1 (ESI,†
Fig. S6).6,15 The two crucial tailoring steps, epoxidation and
alkyl oxidation, are catalysed by CYPs, RufS and RufM (Fig. 1).
Genetic experiments by Ma et al. in Streptomyces SCSIO ZH16
showed that knocking out ilaL (rufM homologue, 99.7% iden-
tity) produced epoxidised rufomycin 2 while an ilaR (rufS
homologue, 99.6% identity) mutant, produced rufomycins
8–10, which are not epoxidised, indicating that IlaL and IlaR
activity is not dependent on the action of the other enzyme, but
not indicating a preferred order (Fig. 1).15 RufM/IlaL is thus
proposed to catalyse sequential two electron oxidations to
generate the aldehyde and carboxylic acid, but genetic experi-
ments cannot rule out the possibility of other enzyme(s)
catalysing some oxidative steps. If RufM/IlaL is responsible
for all oxidations, the aldehyde intermediate 3 must be released
from the RufM/IlaL active site, where it spontaneously cyclises
to give the cyclic hemiaminal 4/5 (Fig. 1). It has not been shown
if 4/5 are intermediates or dead ends in the RufM catalytic
cycle. These questions and the roles of RufM and RufS in
introducing key functionality, motivated us to investigate them
in vitro.
Rufomycins B 1, A 4/5 and C 6 and rufomyazine (Fig. 1) were
isolated from S. atratus DSM41673 as both substrates and standards
for RufM and RufS in vitro reactions (ESI,† Fig. S7–S10).16 Identifi-
cation of rufomycins from S. atratus culture extracts was facilitated
by feeding 13C-2-L-leucine, resulting in triple-13C-labelled rufomycins
and singly labelled rufomyazine 11 (ESI,† Fig. S11 and S12).
Rufomycins 1, 4, 5, 6, identified by LC-HRMS and characteristic
absorbance at 222, 282 and 355 nm, were observed in the same
relative abundance as previously reported (ESI,† Fig. S4).15 Rufomy-
cin C 6 and rufomyazine 11 were isolated in sufficient quantities for
NMR characterisation (ESI,† Fig. S13 and S14).15,16 Interestingly,
under these growth conditions, rufomyazine is more abundant than
any rufomycins (ESI,† Fig. S4). Rufomyazine is analogous to cyclo-
marazine, a shunt metabolite in cyclomarin biosynthesis, and may
result from offloading by a type II thioesterase from module 2 of
RufT,17 following stalling of the dipeptide on module 2 due to the
absence of L-3-nitrotyrosine on module 3 (ESI,† Fig. S6).16,17
With substrates and standards in hand, we investigated the
function of both CYPs. RufS (and homologue IlaR) has high
identity to CymV (51% identity) from cyclomarin biosynthesis,
which has been shown to catalyse epoxidation of the prenylated
tryptophan moiety (Fig. 1).17 RufS was overproduced in E. coli
as an N-His6 tagged fusion protein with a Soret band at 420 nm
(Fig. 2A). To demonstrate its activity, RufS was incubated with
rufomycin B 1, NADPH and redox partners ferredoxin (Fd) and
ferredoxin reductase (Fr) (Spinach, Aldrich). Analysis of the
reactions by LC-HRMS showed conversion of rufomycin B 1
to a single new product, not detected in S. atratus culture, but
corresponding to epoxidised rufomycin 2 (Fig. 2B and ESI,†
Table S8).
Subsequently, RufM was produced as an N-terminal His6
tagged SUMOylated fusion protein, with a Soret band at 417 nm
(Fig. 2A). RufM is 44% identical to the putative d-leucinyl
hydroxylase CymS in cyclomarin A biosynthesis.17 However,
based on the presence of oxidised leucine in the shunt meta-
bolite, cyclomarazine, CymS is proposed to catalyse hydroxyla-
tion of leucine or PCP bound leucine rather than the
cyclomarin cyclic peptide (Fig. 1).17 To assess its activity, RufM
was incubated with rufomycin B 1. LC analysis shows 3 new
peaks (Fig. 2C). HRMS indicates that the major product is the
carboxylic acid 10 (ESI,† Table S9), and the two smaller peaks
correspond to aldehyde/hemiaminal intermediates 7, 8, 9
(Fig. 2C). Pleasingly, the relative proportions of the rufomycins
detected in RufM assays, correspond to those observed by Ma
et al. from culture extracts of the ilaL (rufM homologue)
mutant.15 Interestingly, a primary alcohol is not observed
under these conditions, nor has an alcohol intermediate been
isolated from cultures of S. atratus strains DSM41673 or SCSIO-
ZH16. However, Zhou et al., reported an alcohol containing
rufomycin isolated from Streptomyces strain MJM3502, indicat-
ing that RufM may produce, and release, an alcohol
intermediate.14 We hypothesised that the availability of elec-
tron donor proteins, Fr and Fd, may influence the product
profile. When the concentration of both electron donors was
reduced (0.5, 0.25) the proportion of intermediates 8/9
increased (Fig. 2C). Additionally, a small peak with mass
corresponding to the alcohol 13 is observed (ESI,† Table S10).
We then asked if RufM, on releasing the aldehyde intermediate,
can rebind it and convert it to rufomycin C 6. Incubation of
RufM with hemi-aminal and epoxide containing rufomycin A
4/5, produced rufomycin C 6, demonstrating that RufM can
accept rufomycin A 4/5 and rufomycin B 1 as substrates (Fig. 2D
and ESI† Table S11). Interestingly, conversion of rufomycin A
4/5 to rufomycin C 6 is incomplete. Aldehyde 3 is in equilibrium
with hemiaminal 4/5.15 RufM is likely to preferentially bind the
aldehyde or corresponding gem-diol, and slow interconversion
between these species may result in slow binding to RufM and
Fig. 2 RufS and RufM characterisation: (A) UV-visible spectra of RufS
(black) and RufM (blue). (B) LC analysis of RufS with rufomycin B 1 over
time (C) LC-HRMS analysis of RufM reactions with 1 with decreasing
concentrations of redox partners Fd, Fr. (D) LC-HRMS analysis of reactions
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low conversion. This is supported by our reaction of 4/5 with
semicarbazide, to trap intermediate aldehyde 3, which gave just
40% conversion after 72 hours (ESI,† Fig. S15).18
Having demonstrated the activity of both RufM and RufS in
isolation, we aimed to prove that the products of these reac-
tions were intermediates in the biosynthesis of Rufomycin C 6
and to investigate if there was a preferred order of reaction.
This had the added benefit of proving the identity of inter-
mediate products as they could be converted to rufomycin C 6
for which we have a standard. Thus, oxidation of rufomycin B 1
to rufomycin C 6 was carried out using sequential reactions
where rufomycin B 1 was oxidised by one enzyme, the products
extracted and analysed, then used as substrate(s) for reaction
with the second enzyme (Fig. 3).
Analysis of the RufM reaction shows the presence of remain-
ing rufomycin B 1 and the fully oxidized carboxylic acid product
10 with low levels of intermediates (Fig. 3A). Following incuba-
tion of the extracted mixture with RufS, rufomycin B 1 is almost
completely converted to epoxide 2 and carboxylic acid 10 is
converted to rufomycin C 6 (Fig. 3A and ESI,† Table S12).
Similarly, RufS was incubated with rufomycin B 1, and the
products extracted, then used as substrates for RufM. Analysis
shows total conversion of both epoxidised rufomycins by RufM
after 60 minutes to produce carboxylic acid 10 and rufomycin C
6 (Fig. 3B). Epoxide 2 is thus confirmed for the first time as a
substrate for RufM (ESI,† Table S13).
The results indicate that RufS and RufM accept several
rufomycin derivatives and indicate a preferred order of RufS
followed by RufM. We tested RufM/RufS promiscuity further,
incubating them separately with rufomyazine 11, which con-
tains both moieties modified in rufomycin, however the differ-
ences in size and conformation of rufomyazine were
unsurprisingly, not tolerated by either enzyme, and no oxida-
tion products were detected (ESI,† Fig. S16).
Finally, we investigated if the in vivo product profile is
replicated when both enzymes are present. Incubation of RufM
and RufS (1 : 1 ratio) with rufomycin B 1 showed complete
conversion to rufomycin C 6 (Fig. 3C and ESI,† Table S14).
The result is consistent for different enzyme ratios. No inter-
mediates were detected, indicating a greater affinity of both
enzymes for the intermediates over rufomycin B 1. Lowering
concentrations of electron donors (Fd/Fr) led to very modest
increases in intermediates 2, 4/5 (Fig. 3D and ESI,† Table S15).
Taken together, our results confirm that, like CymV in cyclo-
marin biosynthesis, RufS performs the vital epoxidation of the
prenylated L-tryptophan moiety.15,17 We unambiguously show that
RufM sequentially oxidises a leucine residue to form hemiaminal
and carboxylic acid products. Furthermore, our data demonstrates
that alcohol and aldehyde intermediates are released and the
aldehyde at least, can rebind. Our data in combination with the
accepted mechanism of CYP hydroxylation, involving H abstraction
and oxygen rebound, leads us to propose a complex catalytic cycle
for RufM (Fig. 4A).19 Other CYPs catalyse sequential oxidations
including TxtC, which hydroxylates an aliphatic carbon, releases
the product and rebinds it in a different orientation to oxidise an
aromatic carbon.19,20 Substrate reorientation is not required for
RufM, as the same carbon is oxidised. SaAcmM (42% identity to
RufM) catalyzes the sequential oxidation of an L-proline moiety in
actinomycin biosynthesis. Both the 4-hydroxyproline (actinomycin
X0) and 4-oxoproline (actinomycin X2) derivatives were detected,
indicating like RufM, product release prior to a second round of
oxidation.21 However, what determines whether a CYP catalyses
single or multiple oxidations at a single position is not known.19
Sequence alignment shows that it is not due to differences in the
catalytically important I helix, as while RufM does not contain the
conserved motif, SaAcmM does (Fig. 4B).22
We have however demonstrated that release of partially oxidised
intermediates is enhanced by reduced availability of electron donors.
Fig. 3 Sequential and one pot oxidation reactions of RufS and RufM with rufomycin B 1. (A) Oxidation by RufM followed by epoxidation by RufS. Analysis
by LC-HRMS. Traces are EICs of 1012.58 m/z, 1028.58 m/z, 1026.56 m/z, 1042.56 m/z and 1058.55 m/z. (B) Oxidation of rufomycin B 1 by RufS followed
by RufM, analysis by LC-HRMS shown as in A. All reactions contain rufomycin B 1 (40 mM), 1 h, 30 1C in Tris (25 mM, pH 8), ferredoxin (Fd) and ferredoxin
reductase (Fr) and NADPH (1 mM). Rufomycin B (green) and rufomycin C (orange) are standards purified from S. atratus culture. (C) LC-HRMS analysis of
1 pot reactions of RufS and RufM with rufomycin B 1 (D) LC-HRMS analysis of one pot reactions of RufS and RufM with rufomycin B 1 with various ratios of
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Differences in rufomycin oxidation product profile between in vivo
and in vitro RufM reactions could result from a combination of
factors including secretion, in vivo, of reactive, potentially toxic,
aldehydes/hemiaminals 3–5 from the cell as a possible resistance
mechanism. Differences in rufM/rufS expression levels may play a
role, although changes in RufM/RufS ratios tested here, did not
result in a change in product profile. Thus based on our data, the
most significant factor in explaining differences between in vivo and
in vitro oxidation is likely to be the use of non-native electron
transport donors, as also suggested for differences observed in
CYP (PtlI) catalysed sequential oxidation in pentalenolactone
biosynthesis.23 This result illustrates the possibility of modulating
the nature of CYP products by manipulating electron transfer and
warrants further study.24
While the one-pot reaction of RufM and RufS with Rufomy-
cin B 1, produced a different product profile to bacterial culture,
the unexpected formation of a single product is welcome
(Fig. 3C). It represents clean conversion, under mild conditions,
of a complex cyclic peptide via four, two electron oxidations and
the concomitant introduction of two new stereocentres.
CYPs are increasingly attractive to industry as biocatalytic agents
thanks to advances such as directed evolution, designed enzymes,
ancestral sequence reconstruction and use of inexpensive cofactor
surrogates.25–28 However, our work underscores the difficulties of
predicting substrate preference or chemistry catalysed by CYPs, even
where they have high sequence identity to enzymes of known function.
Greater understanding is needed to facilitate development of more
CYPs as catalysts for functionalization of high value compounds.
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Fig. 4 (A) Proposed catalytic cycle of RufM based on this work and
accepted CYP oxygen rebound hydroxylation mechanism.1 Cmp I =
compound I, active oxidising intermediate. (B) Aligned I helix sequences
(Clustal Omega) of RufM, CymS and SaAcM. I helix boundary defined by
SaAcM structure (5NWS21). Conserved motif = AGxD/ET.
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